Glaxo Probes Complaint on China Sales of Botox
This article is for subscribers only.
GlaxoSmithKline Plc is investigating a complaint about how employees in China sell the Botox wrinkle treatment to doctors, adding to the U.K.’s drugmaker woes in the country as Chinese police probe allegations of corruption.
The same whistle-blower who made previous accusations about corruption at Glaxo in China apparently is behind the Botox complaint, Simon Steel, a company spokesman in London, said in an e-mail today. The whistle-blower says salespeople gave doctors cash and perks for prescribing the product, the Wall Street Journal reported today, citing internal documents and e-mails it reviewed.